Stay updated with breaking news from Study Design. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardiometabolic health, today announced...
This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary am
The Global Non-Alcoholic Steatohepatitis Clinical Trials Market Size will be worth around US$ 2.6 billion in 2022, according to Future Market Insights. However, between 2022 and 2032, the market is likely to develop significantly, with a projected growth rate of 7%, which is higher than the historical increase. With...
Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema Real-world data reinforce that...
‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...